

## 2025 Corporate Governance Statement

---

The Board of Prescient Therapeutics Limited (“Prescient” or the “**Company**”) is responsible for the overall corporate governance of Prescient and the entities it controls (together, the “**Group**”). The Board believes that good corporate governance provides the framework for accountability, responsibility, transparency and fairness; and enhances investor confidence.

The ASX Listing Rules require listed companies to prepare a statement disclosing the extent to which they have complied with the recommendations of the ASX Corporate Governance Council (“**Recommendations**”) during the reporting period. The Recommendations are not prescriptive, such that if a company considers a recommendation to be inappropriate having regard to its own circumstances, it has the flexibility not to follow it. Where a company has not followed all the Recommendations, it must identify which Recommendations have not been followed and provide reasons for not following them.

This Corporate Governance Statement (“**Statement**”) discloses the extent to which Prescient has followed the Recommendations, or where appropriate, indicates a departure from the Recommendations with an explanation. This Statement should be read in conjunction with the material on our website [www.ptxtherapeutics.com](http://www.ptxtherapeutics.com), including the 2025 Annual Report.

This Statement is current as of 20 August 2025 and has been approved by the Board of Directors of Prescient Therapeutics Limited.

### **PRINCIPLE 1: LAY SOLID FOUNDATIONS FOR MANAGEMENT AND OVERSIGHT**

#### **Recommendation 1.1 - Role of the Board and Management**

The role of the Board is to set and approve the strategic direction of the Group, guide and monitor the management of the Company and its businesses, and oversee the corporate governance framework with respect to the Group’s affairs. The Board aims to protect and enhance the interests of its shareholders, while taking into account the interests of other stakeholders, including employees, suppliers, and the wider community.

The Board has a formal Board Charter which is available on our website at <https://prescienttherapeutics.investorportal.com.au/corporate-governance-and-directory/> that clearly sets out those matters expressly reserved for the Board’s determination and those matters delegated to management.

The Board delegates responsibility for the day-to-day management of the Company and its businesses to the Chief Executive Officer (**CEO**). The CEO is supported by the senior executive team and delegates authority to appropriate senior executives for specific activities and transactions via a formal Delegations of Authority policy. The Board maintains ultimate responsibility for strategy, control and risk profile of the Group.

#### **Recommendation 1.2: Appointment of Directors**

The Remuneration and Nomination Committee makes recommendations and facilitates the selection and appointment of Directors. Before the Board appoints a new Director or puts forward a candidate for election, the Remuneration and Nomination Committee will ensure that appropriate background checks are undertaken.

We provide our shareholders with all material information in our possession that is relevant to their decision on whether or not to elect or re-elect a Director through a number of channels, including via the notice of meeting and other information contained in the 2025 Annual Report.

#### **Recommendation 1.3: Appointment Terms**

Upon appointment, each Director receives a letter of appointment which sets out the formal terms of their appointment. Directors also receive a deed of indemnity, insurance and access.

Each senior executive has a written contract with the Company, setting out the terms of his or her appointment, including remuneration entitlements and performance requirements.

#### **Recommendation 1.4: Company Secretary**

The Board is supported by the Company Secretary, whose role includes advising the Board on governance matters, assisting the Board with meetings and directors' duties, and acting as an interface between the Board and senior executives across the Group. The Board and individual Directors have access to its Company Secretary.

Under the Company's governance framework, the Company Secretary is accountable to the Board, through the Chair, on all matters regarding the proper functioning of the Board. The Board is responsible for the appointment of the Company Secretary.

Details regarding Prescient's Company Secretary, including experience and qualifications, is set out in the Directors' Report in our 2025 Annual Report.

#### **Recommendation 1.5: Diversity Policy**

The Prescient workforce comprises individuals with diverse skills, backgrounds, perspectives and experiences and this diversity is valued and respected. To demonstrate the Company's commitment to developing measurable objectives to achieve diversity and inclusion in its workplace, the Company has implemented a Diversity Policy which can be viewed at

<https://prescienttherapeutics.investorportal.com.au/corporate-governance-and-directory/>.

The Company's policy has meritocracy as a guiding principle and seeks to align the Company's management systems with its commitment to continue to develop a culture that values and achieves diversity in its workforce and on its Board.

The Board and management consider building a diverse and inclusive workforce as paramount to gaining the best insight into the needs of our stakeholders. A diversity of perspectives and backgrounds also strengthens creativity and innovation in teams. Particular focus is paid to achieving a balance of men and women in senior management positions across the Group. The Board notes that diversity is a multi-faceted consideration involving gender, gender identity or expression, age, race, ethnicity, disabilities, marital status, national origin, socio-economic status, family responsibilities, religious beliefs, cultural background, and sexual orientation. It also refers to diverse ways of thinking and ways of working.

The Company's strategy includes being highly capital efficient while successfully utilising the human resources necessary to conduct state-of-the-art and high-quality operations. To achieve this, we have limited our internal staff to a handful of highly talented and experienced executives and outsourced some of our operations. These outside firms include hospitals, clinical research organisations and contract manufacturing organisations. We believe that inclusion of the populations in these firms in the evaluation of the Company's diversity would significantly increase the percentages of women and other measures.

The composition of women on the Board; in senior executive positions; and across the entire organisation as at 30 June 2025 is as follows.

- Women on the Board – 40%
- Women in senior executive positions – 60%
- Women across the entire organisation – 71%

The Company values diversity and recognises the benefits it can bring to the organisation's ability to achieve its goals. Due to the current size of the Company's operations and the existing composition makeup, the Board has not set measurable target to increase the number of women on the Board, in Senior Executive positions, and across the organisation.. The Board also values diversity when considering external service providers. The Directors periodically review the Company's policies in the context of the principles of a Diversity Policy as

outlined in Recommendation 1.5.

The Company's key measurable objectives for the financial year is to build on diversity outcomes across the business, including that opportunities exist for all genders and people from a broad range of backgrounds. The Remuneration and Nomination Committee will continue to review the measurable objectives annually.

#### **Recommendation 1.6: Board Performance Assessment**

The Board is committed to formally evaluating its performance, the performance of its committees and individual Directors, as well as the governance processes supporting the Board. The Board does this through an annual assessment process.

In the year ended 30 June 2025, the review process involved:

- Completion of a questionnaire/survey by each Director and senior executives, facilitated by the Company Secretary;
- Preparation and provision of a report to each Director with feedback on the performance of the Board based on the survey results; and
- Board and/or Committee meetings to discuss and document any areas and actions for continuous improvement.

An analysis of the data collected indicated that the Board is functioning effectively against the majority of its criteria. Certain opportunities were identified to improve Board effectiveness and these will be measured against in the FY26 review.

#### **Recommendation 1.7: Senior Executive Performance Assessment**

Senior Executives are appointed by the CEO and ratified by the Board. Key Performance Indicators (KPIs) for senior executives contain specific financial and non-financial objectives. KPIs are approved annually by the Board, and performance against KPIs is evaluated annually. In the case of the CEO, the performance review is conducted by the Chair and the results are reported to the Board. Performance evaluations were undertaken during the reporting period by the Company in accordance with this process.

### **PRINCIPLE 2 – BOARD STRUCTURE**

#### **Recommendation 2.1: Nomination Committee**

The Company's Remuneration and Nomination Committee Charter provides for the creation of a committee, with at least three members, a majority of whom are independent Directors, and which must be chaired by an independent Director. The Remuneration and Nomination Committee Charter is available on our website at <https://prescienttherapeutics.investorportal.com.au/corporate-governance-and-directory/>.

The Board has established a Remuneration and Nomination Committee which consists of three members, all of whom are independent Directors. During the financial year 2025 the Committee was comprised of:

- Dr James Campbell – Independent Chair of the Committee
- Mr Steven Engle – Independent Member of the Committee\*
- Dr Ellen Feigal – Independent Member of the Committee
- Dr Gavin Shepherd – Independent Member of the Committee \*\*

\* Mr Engle resigned on 30 March 2025

\*\* Dr Shepherd was appointed as an independent Member of the Committee on 18 July 2024

All Directors have relevant experience as shown in their biographies in the Directors Report.

Details of meetings held by the Committee during the year and member attendance are set out in the 2025 Directors' Report of the company's Annual Report.

In accordance with the Company's Remuneration and Nomination Committee Charter the primary function of

the Committee is to assist the Board to carry out the following:

- review director competence standards;
- review Board succession plans;
- evaluate the Board’s performance;
- make recommendations for the appointment and removal of directors to the Board; and
- make recommendations to the Board on recruitment, retention and termination policies for senior management.

**Recommendation 2.2: Board Skills Matrix**

Our objective is to have an appropriate mix of expertise and experience on our Board so that it can effectively discharge its corporate governance and oversight responsibilities. It is the Board’s view that the current Directors possess an appropriate mix of relevant skills, experience, expertise and diversity to enable the Board to discharge its responsibilities and deliver the Company’s strategic objectives. This mix is subject to review on a regular basis as part of the Board’s performance review process.

The skills and experience represented in the Board and relevant to the Company’s business are set out in the matrix below and following the Company’s annual performance review, it is satisfied that it meets expectations in all of these categories:

<b>Skills and experience</b>	
Strategy	Stakeholder communication and engagement
Policy Development	Safety and Social Responsibility
Financial analysis and capital markets expertise	Client Engagement
Risk and compliance oversight	HSE
ASX Governance	Environmental and Sustainability
Information technology strategy and data governance	Clinical Development
Executive Management	Leadership
Business and Commercial Experience Operations	Ethics and Integrity
Board Experience	Contribution
Capital Markets Experience	Crisis Management
Biotechnology & Pharmaceutical	Previous Board Experience
Legal and regulatory approval	Corporate History

To the extent that any skills are not directly represented on the Board, they are augmented through management and external advisors. Full details of each Directors’ relevant skills and experience are set out in the Company’s 2025 Annual Report.

**Recommendation 2.3: Independent Directors**

An independent director is a non-executive director who is not a member of management and free from any business or other relationship that could materially interfere with, or could reasonably be perceived to materially interfere with, the independent exercise of judgement.

The Board regularly assesses the independence of each Non-Executive Director in light of the information which each Director is required to disclose in relation to any material contract or other relationship with the Company in accordance with the Director’s terms of appointment, the Corporations Act 2001, the Board Charter.

When appointing an independent director or reviewing the independence of its Directors’, the Board will have regard to the definition of independent director and the factors set out in the Recommendations, in particular the factors relevant to assessing the independence of a director set out in Recommendation 2.3.

The Board’s assessment of each current Director is set out below.

Name	Position	Appointment Date	Status
Steven Engle*	Non-Executive Chair	2 June 2014	Independent
Steven Yatomi-Clarke**	Managing Director & CEO	17 November 2014	Non-Independent
James Campbell***	Non-Executive Chair	28 November 2014	Independent
Allen Ebens	Non-Executive Director	1 June 2020	Independent
Ellen Feigal	Non-Executive Director	15 May 2023	Independent
Gavin Shepherd	Non-Executive Director	4 July 2024	Independent
Melanie Farris****	Non-Executive Director	10 April 2025	Independent

\* Steven Engle resigned on 30 March 2025

\*\* Steven Yatomi-Clarke resigned on 19 January 2025

\*\*\* James Campbell was appointed as Chair on 30 March 2025

\*\*\*\* Melanie Farris was appointed on 10 April 2025

The Board considers that Dr Campbell, Dr Ebens, Dr Feigal, Dr Shepherd, and Ms Farris are free from any business or any other relationship that could materially interfere with, or reasonably be perceived to interfere with, the exercise of their unfettered and independent judgement and is able to fulfil the role of independent director for the purpose of the Recommendations. Before Mr Engle resigned on 30 March 2025, he was considered an independent director.

Before Mr Yatomi-Clarke resigned he was not considered by the Company to be independent as he held an executive role with the Company.

#### **Recommendation 2.4: Majority Independence**

As at the date of this Statement, the Company is in compliance with Recommendation 2.4, since all Board Directors are deemed independent. The current Board composition reflects an appropriate balance of skills, expertise and experience to fulfil its obligations to act in the best interests of the Company and all stakeholders. The Board also considers that there are appropriate safeguards in place including policies and protocols to ensure independent thought and decision making.

It is noted that the composition of the Board will be reassessed in the future in line with changes in the Group's operations and will be adjusted as deemed appropriate. The Board will consider the Recommendations in assessing any future changes in Board composition.

Further information regarding our Directors, including their experience and qualifications, is set out in the Directors' Report of our 2025 Annual Report.

#### **Recommendation 2.5: Board Chair**

The Chair, Dr James Campbell is considered an independent Director. The Chair provides leadership to the Board in relation to all Board matters and is responsible for ensuring that the Board meets its responsibilities under the Board Charter. His role is set out in more detail in the Board Charter.

The roles of Chair and Chief Executive Officer are exercised by different individuals, being Dr James Campbell and Mr James McDonnell respectively. The Company does not have a Managing Director.

#### **Recommendation 2.6: Induction, Education and Training**

New Directors are provided with copies of all relevant documents and policies governing the Company's business, operations and management, at the time of joining the Board. All Directors are provided with ongoing professional development and training opportunities to enable them to develop and maintain their skills and knowledge. Directors are also encouraged to personally undertake appropriate training and refresher courses as appropriate to maintain the skills required to discharge their obligations to the Company.

### **PRINCIPLE 3 – ACT ETHICALLY AND RESPONSIBLY**

### **Recommendation 3.1: Statement of Values**

Prescient's values, outlined below, are the guiding principles and norms that define what type of organisation it aspires to be and what it requires from its Directors.

#### **CORE VALUES**

Care for patient welfare  
Responsibility  
Accountability  
Integrity  
Ambition  
Forward thinking  
Pragmatism

Prescient's Executive Team are responsible for instilling these values across the organisation.

### **Recommendation 3.2: Code of Conduct**

The Board recognises the need to observe the highest standards of corporate practice and business conduct. Accordingly, the Board has adopted a Code of Conduct (**Code**) designed to:

- provide a benchmark for professional behaviour throughout the Group;
- support the Company's business reputation and corporate image; and
- make Directors' and employees aware of the consequences if they breach the Code.

The Code can be found on our website at <https://prescienttherapeutics.investorportal.com.au/corporate-governance-and-directory/>. The key aspects of this Code are to:

- act fairly with honesty and integrity in the best interests of the Company and in the reasonable expectations of shareholders;
- act in accordance with all applicable laws, regulations, and the Company policies and procedures;
- have responsibility and accountability for individuals for reporting and investigating reports of unethical practices; and
- use the Company's resources and property properly.

The Code sets out the Company's policies on various matters including ethical conduct, business conduct, compliance, privacy and security of information.

### **Recommendation 3.3: Whistleblower Protection Policy**

The Whistleblower Protection Policy affirms that the Company is committed to the highest standards of conduct and ethical behaviour in all of its business activities. The Company supports a culture of honest and ethical behaviour in ensuring good corporate compliance and governance. The policy sets out, amongst other things, instances of suspected misconduct which can be reported, internal and external reporting avenues, and summarises the protections offered to whistleblowers.

Any material breach of the Company's policies, and/or any notification or anticipated notification under the Whistleblower Protection Policy, is reported to the Board.

The Whistleblower Protection Policy is available on the Company's website <https://prescienttherapeutics.investorportal.com.au/corporate-governance-and-directory/>.

### **Recommendation 3.4: Anti-bribery and Corruption Policy**

The Anti-Bribery and Corruption Policy affirms that the Company is committed maintain high standards of integrity and accountability in conducting its business. The policy provides a framework of guidelines and principles to encourage ethical behaviour in the conduct of business.

Any material breach of the Company's policies, including any breach of the Anti-Bribery and Corruption Policy, is reported to the Board.

The Anti-Bribery and Corruption Policy is available on the Company's website <https://prescienttherapeutics.investorportal.com.au/corporate-governance-and-directory/>.

## **PRINCIPLE 4 – SAFEGUARD INTEGRITY IN CORPORATE REPORTING**

### **Recommendation 4.1: Audit and Risk Committee**

The Company's Audit and Risk Committee Charter provides for the creation of an Audit and Risk Committee, with at least three members, a majority of whom are independent Directors, and which must be chaired by an independent Director who is not the Board Chair. The Audit and Risk Committee Charter is available on our website at <https://prescienttherapeutics.investorportal.com.au/corporate-governance-and-directory/>.

The Board has established an Audit and Risk Committee which consists of three members, all of whom are independent Directors. During the financial year 2025 the Committee was comprised of:

- Ms Melanie Farris – Independent Chair of the Committee\*
- Dr James Campbell – Independent Member of the Committee\*\*
- Mr Steven Engle – Independent Member of the Committee\*\*\*
- Dr Allen Ebens – Independent Member of the Committee
- Dr Gavin Shepherd – Independent Member of the Committee

\* Ms Farris was appointed as an independent Chair of the Committee on 10 April 2025

\*\* Dr James Campbell held the role of an independent Chair of the Committee until 10 April 2025.

\*\*\* Mr Steven Engle resigned on 30 March 2025

All Directors have relevant experience as shown in the biographies in the Directors Report.

Details of meetings held by the Committee during the year and member attendance are set out in the Directors' Report of the 2025 Annual Report.

In accordance with the Company's Audit and Risk Committee Charter the primary function of the Committee is to assist the Board to carry out the following:

- review and monitor the integrity of the Company's financial reports and statements;
- monitor the performance and independence of the external auditor; and
- reviewing the consolidated accounts of the company.

The Audit and Risk Committee is responsible for overseeing the entity's risk management and internal controls framework and as set out under Recommendation 7.1.

### **Recommendation 4.2: Assurances**

The CEO and Company Secretary provide an annual declaration to the Board prior to the Board's approval of the Company's full year financial results. This process was followed for the 2025 full year financial results, where the CEO and Company Secretary provided a declaration to the Board that, in their opinion, the financial records have been properly maintained and that the financial statements comply with the appropriate accounting standards and give a true and fair view of the financial position and performance of the Group, and their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively. On this basis, the 2025 full year financial results were approved by the Board.

### **Recommendation 4.3: Verification of integrity of periodic corporate reports**

The Company's external auditor is William Buck Audit (Vic) Pty Ltd (**William Buck**). William Buck attends our Annual General Meeting (AGM), and a representative is available to answer shareholder questions about the conduct of the audit and the preparation and content of the auditor's report.

William Buck's independence declaration is contained in the Directors' Report of the 2025 Annual Report.

Prescient has policies and processes in place to review the accuracy of information disclosed to the market so that investors can make informed investment decisions. These processes include those to verify the integrity of any periodic corporate report that is not audited or reviewed by the external auditor.

The verification process varies depending on the particular report, but generally involves confirmation by individuals responsible for the information that to the best of their knowledge and belief the information is accurate and not misleading; verification of material supporting information or claims made in disclosures; a review of proposed disclosures by internal subject matter experts; and approval by the individual responsible for the corporate report and confirmation that it is accurate, balanced and appropriate for release.

## **PRINCIPLE 5 – MAKE TIMELY AND BALANCED DISCLOSURE**

### **Recommendation 5.1: Continuous Disclosure Policy**

We are committed to providing information to shareholders and to the market in a manner that is consistent with the meaning and intention of the ASX Listing Rules and the Corporations Act.

To comply with these obligations, the Board has adopted a Continuous Disclosure Policy, which is available on our website at <https://prescienttherapeutics.investorportal.com.au/corporate-governance-and-directory/>. This Continuous Disclosure Policy sets out the key obligations of directors and employees in relation to the Company's continuous disclosure requirements.

The Board has overarching responsibility for compliance with continuous disclosure obligations and Board approval is required for certain key matters (as set out in the Continuous Disclosure Policy) and matters may be referred to the Board for approval by the CEO or the Company Secretary.

The Board is committed to the promotion of investor confidence by ensuring that trading in the Company's securities takes place in an efficient, competitive and informed market and in compliance with our Securities Trading Policy (as applicable). In accordance with continuous disclosure obligations under the ASX Listing Rules, the Company has procedures in place to ensure that all price sensitive information is identified, reviewed by management and disclosed to the ASX in a timely manner. The Company website includes a link to all information disclosed to the ASX.

### **Recommendation 5.2: Provide Board with copies of all material market announcements**

Prescient ensures that its Board receives copies of all material market announcements prior to release to the market followed by immediate notification following each release to the market.

### **Recommendation 5.3: Investor Presentations**

In accordance with the recommendation, Prescient ensures that all substantive presentations are released to the market via the ASX Market Announcements Platform. Where appropriate the Company invite security holders to attend the meetings at the which the presentation is being made and provide security holders with the opportunity to participate in the presentation.

## **PRINCIPLE 6 – RESPECT THE RIGHTS OF SECURITY HOLDERS**

### **Recommendation 6.1: Information and Governance**

Information about the Company and its corporate governance policies is available on our website at <https://prescienttherapeutics.investorportal.com.au/corporate-governance-and-directory/>.

The Company also maintains a separate investor page on our website to provide shareholders with links to annual and interim reports, ASX announcements, presentations and other key information.

### **Recommendation 6.2: Investor Relations**

We endeavour to communicate with shareholders and other stakeholders in an open, regular and timely manner so that the market has sufficient information to make informed investment decisions.

Through its shareholder communications, we aim to provide information that will allow existing shareholders, potential shareholders and financial analysts to make informed decisions about the Group's intrinsic value and meet its obligations under the ASX's continuous disclosure regime.

Our investor relations program which includes:

- issuing regular written shareholder communications such as quarterly financial reporting and an Annual Report to address the Company's strategy and performance;
- sending and receiving shareholder communications electronically;
- maintaining the Board and corporate governance and investor sections on our website including posting all announcements after they have been disclosed to the market;
- promoting two-way interaction with shareholders, by supporting shareholder participation at general meetings including encouraging shareholders to send their questions to the Company prior to the annual general meeting and responding to their questions and feedback; and
- ensuring that continuous disclosure obligations are understood and complied with throughout the Group.

Shareholder queries should be referred to the Company Secretary in the first instance.

Our Company Policy for Shareholder Communications Policy is available on our website at <https://prescienttherapeutics.investorportal.com.au/corporate-governance-and-directory/>.

### **Recommendation 6.3: Shareholder Meeting Participation**

The Board regards each general meeting as an important opportunity to communicate with shareholders and it provides a key forum for shareholders to ask questions about the Company, its strategy and performance. At shareholder meetings, the Company will provide an opportunity for shareholders and other stakeholders to hear from and put questions to the Board, management and if applicable our external auditor.

Shareholders are invited to each general meeting. Shareholders are forwarded the Company's Annual Report (for the Company's AGM), if requested, it is otherwise made available on the Company's website, and provided documents relating to each general meeting, being the notice of meeting, any explanatory memorandum and a proxy form.

### **Recommendation 6.4: All substantive resolutions at a security holder meeting are decided by poll**

In order to ascertain the true will of Prescient's security holders attending general meetings, all voting is conducted via poll.

### **Recommendation 6.5: Electronic Communication with Shareholders**

Shareholders are encouraged to take advantage of the benefits of electronic communications by electing to receive communication from the Company and its share registry electronically.

## **PRINCIPLE 7 – RECOGNISE AND MANAGE RISK**

### **Recommendation 7.1: Risk Committee**

The Company's Audit and Risk Committee Charter provides for the creation of an Audit and Risk Committee, with at least three members, a majority of whom are independent Directors, and which must be chaired by an independent Director who is not the Board Chair. The Audit and Risk Committee Charter is available on our website at <https://prescienttherapeutics.investorportal.com.au/corporate-governance-and-directory/>.

The Board has established an Audit and Risk Committee which consists of three members, all of whom are independent Directors. During the financial year 2025 the Committee was comprised of:

- Ms Melanie Farris – Independent Chair of the Committee\*
- Dr James Campbell – Independent Member of the Committee\*\*
- Mr Steven Engle – Independent Member of the Committee\*\*\*
- Dr Allen Ebens – Independent Member of the Committee
- Dr Gavin Shepherd – Independent Member of the Committee

\* Ms Farris was appointed as an independent Chair of the Committee on 10 April 2025

\*\* Dr James Campbell held the role of an independent Chair of the Committee until 10 April 2025.

\*\*\* Mr Steven Engle resigned on 30 March 2025

All Directors have relevant experience as shown in the biographies in the Directors Report of the 2025 Annual Report.

Details of meetings held by the Committee during the year and member attendance are set out in the Directors' Report of the 2025 Annual Report.

In accordance with the Company's Audit and Risk Committee Charter the Committee also has delegated responsibilities in relation to risk management which includes assisting the Board to:

- review and make recommendations regarding the adequacy and integrity of the Company's risk management framework and system of internal controls; and
- reviewing compliance with relevant laws and regulations

#### **Recommendation 7.2: Risk Management Framework**

The Group's risk management framework is supported by the Board of Directors, management, and the Audit and Risk Committee. The Board is responsible for approving and reviewing the Company's risk management strategy and policy. Management is responsible for ensuring that appropriate processes and controls are in place to effectively and efficiently manage risk. Management is responsible for ensuring compliance with and the effectiveness of risk management systems and controls at a divisional level including financial and non-financial risks. Senior executives regularly report to the Board on the Company's risk management systems and processes, as well as key risk matters.

#### **Recommendation 7.3: Internal Audit**

The Company does not currently have an internal audit function as, in light of cost/benefit considerations, the size and scope of the Company's operations does not currently support the operation of such function. The Board has reserved authority to utilise external providers for advice and/or to conduct internal audit/s in the event it feels necessary for assurance on matters material to the Company's operations and performance.

During the past financial year, the Company employed the following process for evaluating and continually improving the effectiveness of its risk management and internal control framework:

- the Audit and Risk Committee considers the need for an internal audit function having regard to the size and complexity of the Company's operations;
- senior management periodically reviews financial and non-financial systems and processes and presents to the Board the objectives and scope, proposed outcomes and any recommendations arising from the review; and
- following recommendations of the Audit and Risk Committee, the full Board considers the risk management and internal control framework and risk matters raised for consideration by management.

#### **Recommendation 7.4: Economic, Environmental and Social Sustainability Risk**

The Company is not subject to any particular or significant single economic, environmental and social sustainability risk. The Company is subject to a range of general economic risks, including macro-economic risks, government policy (including policy regarding research and development), general business conditions, changes

in technology and many other factors.

The Board does not believe the Company has any material exposure to economic and social sustainability risks at the present time.

## **PRINCIPLE 8 – REMUNERATE FAIRLY AND RESPONSIBILITY**

### **Recommendation 8.1: Remuneration Committee**

The Company's Remuneration and Nomination Committee Charter provides for the creation of a Remuneration and Nomination Committee, with at least three members, a majority of whom are independent Directors, and which must be chaired by an independent Director. The Remuneration and Nomination Committee Charter is available on our website at <https://prescienttherapeutics.investorportal.com.au/corporate-governance-and-directory/>.

The Board has established a Remuneration and Nomination Committee which consists of three members, all of whom are independent Directors. During the financial year 2025 the Committee was comprised of:

- Dr James Campbell – Independent Chair of the Committee
- Mr Steven Engle – Independent Member of the Committee\*
- Dr Ellen Feigal – Independent Member of the Committee
- Dr Gavin Shepherd – Independent Member of the Committee \*\*

*\* Mr Engle resigned on 30 March 2025*

*\*\*Dr Shepherd was appointed as an independent Member of the Committee on 18 July 2024*

Details of meetings held by the Committee during the year and member attendance are set out in the Directors' Report of the 2025 Annual Report.

In accordance with the Company's Nomination and Remuneration Committee Charter the Committee has delegated responsibilities in relation to remuneration matters which includes assisting the Board to make recommendations to the Board on:

- executive remuneration and incentive policies;
- the remuneration packages of senior management;
- incentive schemes;
- superannuation arrangements; and
- the remuneration framework for directors.

### **Recommendation 8.2: Remuneration Policies and Practices**

The Remuneration and Nomination Committee is responsible for determining and reviewing remuneration policies for the directors and senior executives. If necessary, it obtains independent advice on the appropriateness of remuneration packages given trends in comparable companies and in accordance with the objectives of the Company.

Details of the Company's remuneration practices for its Directors and senior executives are disclosed in the Remuneration Report in the Company's 2025 Annual Report. The Remuneration Report highlights the balance between fixed pay, short term incentive and long-term incentives, and includes details of the remuneration paid and the relationship to the Company's performance.

### **Recommendation 8.3: Equity Based Remuneration Scheme**

The Company has established an equity-based remuneration scheme as part of its broader remuneration framework to align the interests of directors, executives and key employees with those of shareholders, and to support long-term value creation. PTX has a Securities Trading Policy, which provides that participants must not, without prior approval of the CEO, enter into transactions (whether through the use of derivatives or otherwise) which limit the economic risk of participating in the scheme. The Share Trading Policy is available on our website at <https://prescienttherapeutics.investorportal.com.au/corporate-governance-and-directory/>.